Search
Now showing items 1-7 of 7
Ultrastructural Analyses Of The Novel Chimeric Hemostatic Agent Generated Via Nanotechnology, Abs Nanohemostat, At The Renal Tissue Level
(2016)
Ankaferd Blood Stopper (ABS), a hemostatic agent of plant origin, has been registered for the prevention of clinical hemorrhages. Currently there is no data regarding the ultrastructural analysis of ABS at the tissue level. ...
Splenic Artery Embolization With Ankaferd Blood Stopper In A Sheep Model
(Aves, 2016)
PURPOSE Splenic artery embolization is a minimally invasive therapeutic procedure utilized in a number of disorders. Ankaferd blood stopper (ABS) is a novel hemostatic agent with a new mechanism of action independent of ...
Qualitative/Chemical Analyses of Ankaferd Hemostat and Its Antioxidant Content in Synthetic Gastric Fluids
(2016)
Introduction. Ankaferd hemostat (ABS) is the first topical haemostatic agent involving the red blood cell-fibrinogen interactions. The antihemorrhagic efficacy of ABS has been tested in controlled clinical trials. The drug ...
The Impact Of Jak1/Jak2 Inhibitor Ruxolitinib On The Spleen Size And Symptom Burden In Myeloproliferative Diseases
(Akad Doktorlar Yayınevi, 2016)
Ruxolitinib as a JAK1 and JAK2 inhibitor drug has recently been approved for the treatment of patients with high-or intermediate-risk myelofibrosis with symptomatic splenomegaly. Clinical development of ruxolitinib has ...
The Impact Of Iron Overload On Transplant-Related Complications And Prognosis Of Acute Leukemias
(Akad Doktorlar Yayınevi, 2016)
The impacts of serum iron parameters and/or radiological evidence of systemic iron overload on the prognosis of hematopoietic stem cell transplantation (HSCT) in acute leukemia are controversial. Unfortunately, some of the ...
Idelalisib At The Crossroads Of B-Cell Lymphoproliferative Disorders
(Akad Doktorlar Yayınevi, 2016)
Phosphatidylinositol 3-kinases (PI3Ks) are considered as lipid kinases that are very active in the pathobiology of lymphoproliferative disorders (LPDs). Idelalisib, a selective inhibitor of the delta isoform of PI3K, ...
Molecular Management Of Chronic Lymphocytic Leukemia: Towards A Chemotherapy-Free Approach
(Akad Doktorlar Yayınevi, 2016)
B-cell receptor (BCR) signaling is implicated as a pivotal pathway in tumorigenesis in B-cell malignancies. The inhibitors of Bruton's tyrosine kinase (BTK) and phosphatidylinositide 3-kinase-delta (PI3K), modulating BCR ...